Ionis Pharmaceuticals (IONS) Non-Current Debt (2009 - 2025)
Ionis Pharmaceuticals (IONS) posted quarterly Non-Current Debt of $28.1 million for Q4 2025, down 45.85% year-over-year from $51.9 million in Q4 2024, and down 45.85% quarter-over-quarter from $51.9 million in Q4 2024.
Ionis Pharmaceuticals (IONS) Non-Current Debt (2009 - 2025) Analysis & Trends
Ionis Pharmaceuticals' Non-Current Debt history runs 17 years deep, the most recent figure standing at $28.1 million for Q4 2025.
- In Q4 2025, Non-Current Debt fell 45.85% year-over-year to $28.1 million; the TTM figure through Dec 2025 stood at $28.1 million (down 45.85% YoY), while the FY2025 annual figure was $28.1 million, down 45.85% from the prior year.
- Non-Current Debt for Q4 2025 stood at $28.1 million, down from $51.9 million in the prior quarter.
- The five-year high for Non-Current Debt was $60.0 million in Q2 2021, with the low at $8.8 million in Q1 2023.
- The 5-year median for Non-Current Debt is $59.1 million (2022), against an average of $47.0 million.
- Peak annual rise in Non-Current Debt reached 161.92% in 2023, while the deepest fall reached 85.18% in 2023.
- Ionis Pharmaceuticals' Non-Current Debt stood at $59.7 million in 2021, then plunged by 73.25% to $16.0 million in 2022, then jumped by 161.92% to $41.8 million in 2023, then grew by 24.11% to $51.9 million in 2024, then slumped by 45.85% to $28.1 million in 2025.
- Business Quant data shows IONS's Non-Current Debt at $28.1 million in Q4 2025, $51.9 million in Q4 2024, and $41.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.12 Mn |
| Dec 31, 2024 | 51.92 Mn |
| Dec 31, 2023 | 41.84 Mn |
| Mar 31, 2023 | 8.81 Mn |
| Dec 31, 2022 | 15.97 Mn |
| Sep 30, 2022 | 58.98 Mn |
| Jun 30, 2022 | 59.22 Mn |
| Mar 31, 2022 | 59.46 Mn |
| Dec 31, 2021 | 59.71 Mn |
| Sep 30, 2021 | 59.96 Mn |
| Jun 30, 2021 | 60.02 Mn |
| Mar 31, 2021 | 60.00 Mn |
| Dec 31, 2020 | 59.98 Mn |
| Sep 30, 2020 | 59.97 Mn |
| Jun 30, 2020 | 59.95 Mn |
| Mar 31, 2020 | 59.93 Mn |
| Dec 31, 2019 | 59.91 Mn |
| Sep 30, 2019 | 59.90 Mn |
| Jun 30, 2019 | 59.88 Mn |
| Mar 31, 2019 | 59.86 Mn |